Navigation Links
MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
Date:5/13/2008

ing the fourth quarter of 2008, pending the outcome of its ongoing strategic evaluation.

MOXATAG is the first and only once-daily aminopenicillin therapy approved by the FDA to treat strep throat. Physicians prescribing MOXATAG would be able to provide their patients the convenience of once-daily dosing while utilizing approximately one-half the amount of amoxicillin currently used. According to prescription data from IMS Health, more than 30 million prescriptions were written for strep throat, pharyngitis and tonsillitis in the U.S. in 2007.

Equity Financing in January 2008 Raises $21 Million in Gross Proceeds

On January 28, 2008, MiddleBrook closed a private placement of common stock and warrants to institutional investors, resulting in the receipt of approximately $19.9 million in net proceeds. The transaction included the private placement of 8.75 million shares of MiddleBrook common stock and five-year warrants to purchase an additional 3.5 million shares of common stock.

The Company intends to use the proceeds from the financing to support the manufacture of MOXATAG, and for working capital and general corporate purposes. In addition, the financing is designed to provide the Company with additional financial flexibility in its ongoing strategic discussions.

Process to Explore Strategic Alternatives Ongoing

In February 2008, MiddleBrook announced that it engaged Morgan Stanley as its strategic advisor in the Company's ongoing strategic evaluation process. MiddleBrook is evaluating a full range of available strategic alternatives intended to further enhance shareholder value.

Strategic alternatives the Company may pursue could include, but are not limited to, continued execution of the Company's operating plan, the sale of some or all of the Company's assets, partnering or other collaboration agreements, or a merger or other strategic transaction. There can be no assurance that the exploration of strategic alterna
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The employees of Pharmica ... Washington Crossing, Pennsylvania on Thursday, August 7th to spend ... been looking for different ways that Pharmica could get ... with Pharmica Consulting. “When we heard that we could ... we jumped at the opportunity.” , Pharmica spent their ...
(Date:8/21/2014)... 21, 2014 Sometimes you have to lose the ... new book “From Zero to a Hundred: Finding My Purpose through ... story of surviving a broken family, a childhood of gang violence ... who you were created to be,” Roy said. “I didn’t give ... I know my purpose today of helping others overcome their trials.” ...
(Date:8/21/2014)... Michael E. Steuer , local doctor in ... the Bluff City with recent philanthropy at local synagogue. “The ... United States,” says friend and Rabbi David Julian of Or ... as providing in-house for the needy and teaching Hebrew to ... the local synagogue. And to remain close with the development ...
(Date:8/21/2014)... Drake University’s Phi Gamma Delta (FIJI) and ... cancer research, according to Billy Cundiff, President of Colleen’s ... for the Cleveland Browns, says the money raised by ... Dream Foundation and will fund research to be conducted ... Division of Gynecologic Oncology at the University of Iowa’s ...
(Date:8/21/2014)... Recently, BambooIndustry.com, one of the most famous ... new range of hand scraped bamboo floorings ... an Autumn special offer for these elegant items. According ... a discounted price, up to 25% off; the promotion ... , Providing natural looks and available in different varieties, ...
Breaking Medicine News(10 mins):Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3Health News:Cheap Hand Scraped Bamboo Floorings Recently Unveiled by BambooIndustry.com 2
... Anderson Hospital administration and their ED process improvement ... the ED Patient Throughput Team at ... The ED Patient Throughput Team, responsible for reducing wait times ... three finalists to receive the award for their excellence in ...
... higher in moms-to-be who snore, study finds , THURSDAY, June ... more likely to develop gestational diabetes, new research has found. ... survey when they were between six and 20 weeks pregnant, ... that pregnant women who were frequent snorers -- defined as ...
... ... him uniquely qualified to lead NVCI , ... Las Vegas, NV (PRWEB) June 11, 2009 -- Stephen J. ... as Chairman of the Board for the Nevada Cancer Institute (NVCI) effective July 1, ...
... As a result of the economic climate, high-technology and ... in addition to extending cost controls for their current ... Aon Consulting,s Radford, a leading provider of compensation intelligence ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) , ...
... had best results in study , THURSDAY, June 11 (HealthDay ... diabetes, may also help non-diabetic obese people lose weight when ... Researchers divided 152 obese men and women (with a body-mass ... 241 pounds) into two groups. About 25 percent of the ...
... Researchers at Nationwide Children,s Hospital and Johns Hopkins University ... highly expressed in normal tissues but lost in diseased ... (miRNA) are a class of small RNA molecules that ... in gene expression and in maintaining normal cell development ...
Cached Medicine News:Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 2Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 3Health News:Frequent Snoring in Pregnancy Could Signal Blood Sugar Trouble 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 2Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 4Health News:Diabetes Drug Byetta May Aid Weight Loss in Obese Patients 2Health News:Study shows promise for new cancer-stopping therapy 2
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... DIEGO , Aug. 20, 2014 Trovagene, ... diagnostics, announced today that results from two clinical studies ... conference for the Company,s urine-based diagnostic test for the ... The IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... conjunction with DURECT Corporation,s (Nasdaq: DRRX ) fourth ... listen to the conference call that will be broadcast live ... pm Eastern Time (1:30 pm Pacific Time). (Logo: ... the presentation will be available by accessing DURECT,s homepage at ...
... -- The SimplyGo Portable Oxygen Concentrator by Philips ... continuous flow and pulse does at a weight of only ... lightest weight continuous flow portable concentrator weighed in at a ... voltage meaning anywhere you go in the world you can ...
Cached Medicine Technology:SimplyGo Portable Oxygen Concentrator Now Available 2
... easy-to-use 3800 and 3900/P pulse oximeters ... the proprietary clinical patient motion algorithm ... improved performance:, ,The 3800 and ... rigorous environmental/ mechanical stress testing such ...
... The Acuity LT Central Monitoring Station provides ... and ready to go right out of ... surveillance in specific care areas rather than ... ICU. As patient-to-caregiver ratios continue to climb ...
... 3800 and 3900/P pulse oximeters are ... proprietary clinical patient motion algorithm from ... performance:, ,The 3800 and 3900 ... environmental/ mechanical stress testing such as ...
... Researchers., ,S/5 Collect and S/5 Collect4 provides ... collect data from Datex-Ohmeda monitors. Data can be ... intervals. With S/5 Collect you have ability to ... interface cable or connect directly from S/5 Central. ...
Medicine Products: